Targeting Hyaluronic Acid Family for Cancer Chemoprevention and Therapy

Overview

Journal Adv Cancer Res

Publisher Elsevier

Specialty Oncology

Date 2014 Aug 2

PMID 25081525

Citations 73

Authors

Vinata B Lokeshwar

Summan Mirza

Andre Jordan

Affiliations

Soon will be listed here.

Abstract

Hyaluronic acid or hyaluronan (HA) is perhaps one of the most uncomplicated large polymers that regulates several normal physiological processes and, at the same time, contributes to the manifestation of a variety of chronic and acute diseases, including cancer. Members of the HA signaling pathway (HA synthases, HA receptors, and HYAL-1 hyaluronidase) have been experimentally shown to promote tumor growth, metastasis, and angiogenesis, and hence each of them is a potential target for cancer therapy. Furthermore, as these members are also overexpressed in a variety of carcinomas, targeting of the HA family is clinically relevant. A variety of targeted approaches have been developed to target various HA family members, including small-molecule inhibitors and antibody and vaccine therapies. These treatment approaches inhibit HA-mediated intracellular signaling that promotes tumor cell proliferation, motility, and invasion, as well as induction of endothelial cell functions. Being nontoxic, nonimmunogenic, and versatile for modifications, HA has been used in nanoparticle preparations for the targeted delivery of chemotherapy drugs and other anticancer compounds to tumor cells through interaction with cell-surface HA receptors. This review discusses basic and clinical translational aspects of targeting each HA family member and respective treatment approaches that have been described in the literature.

Citing Articles

Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.

Dana N, Dabiri A, Najafi M, Rahimi A, Ishaghi S, Shariati L Bioeng Transl Med. 2025; 10(2):e10716.

PMID: 40060757 PMC: 11883117. DOI: 10.1002/btm2.10716.

A conditionally replicative adenovirus vector containing the synNotch receptor gene for the treatment of muscle-invasive bladder cancer.

A R, Ueki H, Nishioka S, Yamazaki R, Maekawa M, Kitagawa K Cancer Gene Ther. 2025; .

PMID: 40011711 DOI: 10.1038/s41417-025-00879-8.

Application of Nanomaterials Targeting Immune Cells in the Treatment of Chronic Inflammation.

Ci Z, Wang H, Luo J, Wei C, Chen J, Wang D Int J Nanomedicine. 2024; 19:13925-13946.

PMID: 39735324 PMC: 11682674. DOI: 10.2147/IJN.S497590.

Review on Hyaluronic Acid Functionalized Sulfur and Nitrogen Co-Doped Graphene Quantum Dots Nano Conjugates for Targeting of Specific Type of Cancer.

Sudhakar Patil V, Rupa Bavaskar K, Omprakash Morani D, Suresh Jain A Adv Pharm Bull. 2024; 14(2):266-277.

PMID: 39206392 PMC: 11347733. DOI: 10.34172/apb.2024.043.

The roles of hyaluronan in kidney development, physiology and disease.

Rabelink T, Wang G, van der Vlag J, van den Berg B Nat Rev Nephrol. 2024; 20(12):822-832.

PMID: 39191935 DOI: 10.1038/s41581-024-00883-5.

References

Tan J, Wang X, Li H, Su X, Wang L, Ran L . HYAL1 overexpression is correlated with the malignant behavior of human breast cancer. Int J Cancer. 2010; 128(6):1303-15. DOI: 10.1002/ijc.25460. View

Liu Y, Sun J, Cao W, Yang J, Lian H, Li X . Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm. 2011; 421(1):160-9. DOI: 10.1016/j.ijpharm.2011.09.006. View

Wang X, Liu W, Sun C, Armenian S, Hakonarson H, Hageman L . Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. J Clin Oncol. 2014; 32(7):647-53. PMC: 3927733. DOI: 10.1200/JCO.2013.50.3557. View

Morohashi H, Kon A, Nakai M, Yamaguchi M, Kakizaki I, Yoshihara S . Study of hyaluronan synthase inhibitor, 4-methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL). Biochem Biophys Res Commun. 2006; 345(4):1454-9. DOI: 10.1016/j.bbrc.2006.05.037. View

Porsch H, Bernert B, Mehic M, Theocharis A, Heldin C, Heldin P . Efficient TGFβ-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene. 2012; 32(37):4355-65. PMC: 3778714. DOI: 10.1038/onc.2012.475. View

Karbownik M, Nowak J . Hyaluronan: towards novel anti-cancer therapeutics. Pharmacol Rep. 2014; 65(5):1056-74. DOI: 10.1016/s1734-1140(13)71465-8. View

Lokeshwar V, Young M, Goudarzi G, Iida N, Yudin A, Cherr G . Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Cancer Res. 1999; 59(17):4464-70. View

Bourguignon L, Wong G, Earle C, Krueger K, Spevak C . Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010; 285(47):36721-35. PMC: 2978601. DOI: 10.1074/jbc.M110.162305. View

Saito T, Tamura D, Nakamura T, Makita Y, Ariyama H, Komiyama K . 4-methylumbelliferone leads to growth arrest and apoptosis in canine mammary tumor cells. Oncol Rep. 2012; 29(1):335-42. DOI: 10.3892/or.2012.2100. View

10.

Kudo D, Kon A, Yoshihara S, Kakizaki I, Sasaki M, Endo M . Effect of a hyaluronan synthase suppressor, 4-methylumbelliferone, on B16F-10 melanoma cell adhesion and locomotion. Biochem Biophys Res Commun. 2004; 321(4):783-7. DOI: 10.1016/j.bbrc.2004.07.041. View

11.

Garin T, Rubinstein A, Grigoriadis N, Nedvetzki S, Abramsky O, Mizrachi-Koll R . CD44 variant DNA vaccination with virtual lymph node ameliorates experimental autoimmune encephalomyelitis through the induction of apoptosis. J Neurol Sci. 2007; 258(1-2):17-26. DOI: 10.1016/j.jns.2007.01.079. View

12.

Shi J, Ma R, Wang L, Zhang J, Liu R, Li L . The application of hyaluronic acid-derivatized carbon nanotubes in hematoporphyrin monomethyl ether-based photodynamic therapy for in vivo and in vitro cancer treatment. Int J Nanomedicine. 2013; 8:2361-73. PMC: 3702246. DOI: 10.2147/IJN.S45407. View

13.

Slomiany M, Dai L, Tolliver L, Grass G, Zeng Y, Toole B . Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides. Clin Cancer Res. 2009; 15(24):7593-7601. PMC: 2794991. DOI: 10.1158/1078-0432.CCR-09-2317. View

14.

Balazs E, HOGBERG B, Laurent T . The biological activity of hyaluron sulfuric acid. Acta Physiol Scand. 1951; 23(2-3):168-78. DOI: 10.1111/j.1748-1716.1951.tb00806.x. View

15.

Yoon H, Koo H, Choi K, Lee S, Kim K, Kwon I . Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials. 2012; 33(15):3980-9. DOI: 10.1016/j.biomaterials.2012.02.016. View

16.

Udabage L, Brownlee G, Waltham M, Blick T, Walker E, Heldin P . Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res. 2005; 65(14):6139-50. DOI: 10.1158/0008-5472.CAN-04-1622. View

17.

Lokeshwar V, Cerwinka W, Isoyama T, Lokeshwar B . HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res. 2005; 65(17):7782-9. DOI: 10.1158/0008-5472.CAN-05-1022. View

18.

Rajasagi M, von Au A, Singh R, Hartmann N, Zoller M, Marhaba R . Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization. J Cell Mol Med. 2009; 14(6B):1453-67. PMC: 3829012. DOI: 10.1111/j.1582-4934.2009.00909.x. View

19.

Alaniz L, Garcia M, Gallo-Rodriguez C, Agusti R, Sterin-Speziale N, Hajos S . Hyaluronan oligosaccharides induce cell death through PI3-K/Akt pathway independently of NF-kappaB transcription factor. Glycobiology. 2006; 16(5):359-67. DOI: 10.1093/glycob/cwj085. View

20.

Arai E, Nishida Y, Wasa J, Urakawa H, Zhuo L, Kimata K . Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer. 2011; 105(12):1839-49. PMC: 3251882. DOI: 10.1038/bjc.2011.459. View